Security
Capricor Therapeutics, Inc. Common Stock · CAPR
CAPRNASDAQCommon stockCurrentCIK 1133869Updated Oct 15, 2026
Name history
Nile Therapeutics, Inc. · through Nov 20, 2013SMI PRODUCTS INC · through Sep 19, 2007
CAPR price & chart
Loading TradingView…
NASDAQ:CAPR on TradingView ↗About the company
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.
In the news
Kaplan Fox Urges Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Seek a Leadership Role Before September 28, 2026 ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR ↗
Seeking Alpha
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy - Slideshow ↗
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript ↗
Capricor drops as deramiocel OLE data fails to quell regulatory concerns ↗
Recent filings
SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.
Other Events
Items 8.01, 9.01
SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.
10-Q filing
SCHEDULE 13G/A - filed by TANG CAPITAL MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by RA CAPITAL MANAGEMENT, L.P. regarding CAPRICOR THERAPEUTICS, INC.
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 126,438,207Source | 92,951,613Source | 368,735,835Source | 133,569,011Source | 38,277,453Source | 326,283,517Source | 153,765,973Source | 49,444,442Source | 355,949,294Source | 170,481,086Source | 58,734,327Source | 50,094,910Source |
| Property, Plant and Equipment, NetUSD | 11,068,078Source | 5,315,385Source | 36,346,335Source | 7,995,259Source | 5,617,523Source | 28,502,617Source | 6,133,870Source | 5,893,552Source | 18,312,238Source | 5,561,597Source | 5,560,641Source | 4,588,030Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 19,510,383Source | 68,377,402Source | 20,935,187Source | 23,241,199Source | 10,688,363Source | 105,421,484Source | 28,794,503Source | 6,214,647Source | 287,847,312Source | 11,286,996Source | 14,694,857Source | 9,603,242Source |
| Assets, CurrentUSD | 100,951,681Source | 85,823,371Source | 242,127,977Source | 124,126,546Source | 30,669,223Source | 283,088,809Source | 146,250,984Source | 41,411,922Source | 322,939,756Source | 163,385,267Source | 50,855,472Source | 42,888,734Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,326,543Source | 385,065Source | 4,193,195Source | 1,266,356Source | 837,218Source | 4,478,895Source | 1,413,754Source | 1,125,844Source | 4,751,674Source | 1,500,901Source | 995,776Source | 919,892Source |
| Operating Lease, Right-of-Use AssetUSD | 13,929,710Source | 1,493,611Source | 88,615,221Source | 939,204Source | 1,671,149Source | 13,158,500Source | 1,127,745Source | 1,845,246Source | 13,537,820Source | 1,312,522Source | 2,050,042Source | 2,349,974Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 42,570,952Source | 24,686,654Source | 122,516,945Source | 28,591,955Source | 26,775,147Source | 47,580,884Source | 26,120,506Source | 31,009,504Source | 50,157,149Source | 25,018,750Source | 36,132,860Source | 38,308,816Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 45,717Source | 40,332Source | 58,109Source | 45,712Source | 31,984Source | 57,665Source | 45,677Source | 31,600Source | 57,371Source | 45,582Source | 31,148Source | 25,241Source |
| Retained Earnings (Accumulated Deficit)USD | -274,707,571Source | -192,717,936Source | -379,553,484Source | -250,136,924Source | -180,161,208Source | -338,819,830Source | -224,226,133Source | -169,161,426Source | -304,878,485Source | -199,834,539Source | -159,367,353Source | -137,079,811Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 844,122Source | 96,221Source | -163,541Source | 1,387,574Source | 154,987Source | -253,727Source | 1,811,927Source | 307,701Source | 283,154Source | 1,026,955Source | 235,813Source | 105,244Source |
| Stockholders' Equity Attributable to ParentUSD | 83,867,255Source | 68,264,959Source | 246,218,890Source | 104,977,056Source | 11,502,306Source | 278,702,633Source | 127,645,467Source | 18,434,938Source | 305,792,145Source | 145,462,336Source | 22,601,467Source | 11,786,094Source |
| Additional Paid in Capital, Common StockUSD | 357,684,987Source | 260,846,342Source | 625,877,806Source | 353,680,694Source | 191,476,543Source | 617,718,525Source | 350,013,996Source | 187,257,063Source | 610,330,105Source | 344,224,338Source | 181,701,859Source | 148,735,420Source |
| Liabilities and EquityUSD | 126,438,207Source | 92,951,613Source | 368,735,835Source | 133,569,011Source | 38,277,453Source | 326,283,517Source | 153,765,973Source | 49,444,442Source | 355,949,294Source | 170,481,086Source | 58,734,327Source | 50,094,910Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 28,148,257Source | 20,475,506Source | 32,961,421Source | 28,397,352Source | 22,354,779Source | 33,637,289Source | 22,336,855Source | 26,383,752Source | 35,836,760Source | 21,026,176Source | 31,269,818Source | 23,586,555Source |
| Operating Lease, Liability, CurrentUSD | 120,094Source | 813,634Source | 1,489,838Source | 849,505Source | 792,694Source | 841,135Source | 842,101Source | 771,506Source | 202,376Source | 834,799Source | 749,112Source | 682,039Source |
| Accounts Payable, CurrentUSD | 2,719,416Source | — | 3,079,714Source | 4,812,356Source | — | 3,927,941Source | 5,253,636Source | — | 1,654,754Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 14,422,695Source | 834,889Source | 89,555,524Source | 194,603Source | 1,044,109Source | 13,943,595Source | 407,392Source | 1,249,493Source | 14,320,389Source | 616,315Source | 1,486,783Source | 1,878,070Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 9,932,488Source | — | 16,391,869Source | 7,359,232Source | — | 10,528,351Source | 4,241,118Source | — | 15,557,646Source | — | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 98,600,000Source | 85,000,000Source | — | 122,800,000Source | 29,500,000Source | — | 144,800,000Source | 39,900,000Source | — | 151,500,000Source | 39,500,000Source | 41,400,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -33,941,345Source | -24,391,594Source | -105,043,946Source | -40,467,186Source | -22,287,542Source | -29,019,532Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 534,670Source | 405,450Source | 1,889,041Source | 1,425,214Source | 1,068,882Source | 533,131Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | — | 9,765,164Source | 7,392,396Source | 4,458,578Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -29,254,891Source | -6,433,520Source | -69,811,261Source | -39,995,742Source | -25,596,545Source | 4,916,637Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -154,641,596Source | 23,890,673Source | 97,479,281Source | -116,183,868Source | 5,108,210Source | -35,072,507Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,121,709Source | 896,007Source | 2,904,461Source | 1,166,871Source | 1,311,660Source | 2,000,243Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,470,659Source | 50,354Source | 248,892,296Source | 152,771,749Source | 25,579,950Source | 4,873,838Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 19,510,383Source | 68,377,402Source | 20,935,187Source | 23,241,199Source | 105,421,484Source | 28,794,503Source | 287,847,312Source | 11,286,996Source | 14,694,857Source | 9,603,242Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 1,600Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,997,348Source | 2,051,283Source | — | 3,647,153Source | — | 5,739,399Source | 17,225,260Source | 9,765,164Source | 7,392,396Source | 4,458,578Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 98,600,000Source | 85,000,000Source | — | 122,800,000Source | — | 144,800,000Source | — | 151,500,000Source | 39,500,000Source | 41,400,000Source |
| DepreciationUSD | — | — | 494,725Source | 361,167Source | 561,845Source | 486,278Source | 534,670Source | 405,450Source | 1,889,041Source | 1,425,214Source | 1,068,882Source | 533,131Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | -6,846Source | — | — | — | -81,143Source | -150,673Source | -157,519Source | -112,805Source | -6,041Source | -34,266Source |
| General and Administrative ExpenseUSD | — | — | 5,924,942Source | 3,463,655Source | 14,079,328Source | 5,670,280Source | 9,395,941Source | 6,067,376Source | 23,687,535Source | 14,866,722Source | 12,807,886Source | 10,431,903Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 1,600Source | 1,600Source | 0Source | 0Source | 1,600Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | — | — | — | 3,045,725Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,570,647Source | -12,556,728Source | -40,733,654Source | -25,910,791Source | -33,941,345Source | -24,391,594Source | -105,043,946Source | -40,467,186Source | -22,287,542Source | -29,019,532Source |
| Nonoperating Income (Expense)USD | — | — | 1,713,393Source | 453,152Source | 2,213,566Source | 1,808,343Source | 2,831,508Source | 591,354Source | 3,099,784Source | 2,097,656Source | 1,790,317Source | 677,851Source |
| Operating ExpensesUSD | — | — | 26,284,040Source | 15,271,522Source | 42,945,620Source | 27,717,534Source | 36,772,853Source | 24,982,948Source | 108,142,130Source | 64,835,307Source | 49,255,925Source | 32,248,852Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 237,033,938Source | 152,321,576Source | 25,515,349Source | 4,803,534Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,470,659Source | 50,354Source | 11,858,358Source | — | 64,601Source | 70,304Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 2,261,642Source | — | — | — | — | 0Source | 22,270,465Source | 25,178,066Source | 2,600,000Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | 5,918,055Source | 5,481,938Source | 16,967,799Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 2,261,642Source | — | — | — | — | 0Source | 22,270,465Source | 25,178,066Source | 2,551,469Source |
| Operating Income (Loss)USD | — | — | -26,284,040Source | -13,009,880Source | -42,945,620Source | -27,717,534Source | -36,772,853Source | -24,982,948Source | -108,142,130Source | -42,564,842Source | -24,077,859Source | -29,697,383Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | -40,732,054Source | -25,909,191Source | -33,941,345Source | -24,391,594Source | -105,042,346Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 1,600Source | 1,600Source | 0Source | 0Source | 1,600Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,570,647Source | -12,556,728Source | -40,733,654Source | -25,910,791Source | -33,941,345Source | -24,391,594Source | -105,043,946Source | -40,467,186Source | -22,287,542Source | -29,019,532Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.54Source | -0.38Source | -0.7Source | -0.57Source | -0.59Source | -0.53Source | -2.26Source | -1.15Source | -0.83Source | -1.18Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.54Source | -0.38Source | -0.7Source | -0.57Source | -0.59Source | -0.53Source | -2.26Source | -1.15Source | -0.83Source | -1.18Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 45,716,151Source | 33,090,063Source | 57,926,347Source | 45,709,071Source | 57,434,267Source | 45,636,633Source | 46,478,416Source | 35,218,628Source | 26,778,360Source | 24,552,688Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 45,716,151Source | 33,090,063Source | 57,926,347Source | 45,709,071Source | 57,434,267Source | 45,636,633Source | 46,478,416Source | 35,218,628Source | 26,778,360Source | 24,552,688Source |
| Interest Expense (non-operating)USD | — | — | — | — | — | — | — | — | 3,045,725Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,600Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 5,924,942Source | 3,463,655Source | 14,079,328Source | 5,670,280Source | 9,395,941Source | 6,067,376Source | 23,687,535Source | 14,866,722Source | 12,807,886Source | 10,431,903Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -105,042,346Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,713,393Source | 453,152Source | 2,213,566Source | 1,808,343Source | 2,831,508Source | 591,354Source | 3,099,784Source | 2,097,656Source | 1,790,317Source | 677,851Source |
| Operating ExpensesUSD | — | — | 26,284,040Source | 15,271,522Source | 42,945,620Source | 27,717,534Source | 36,772,853Source | 24,982,948Source | 108,142,130Source | 64,835,307Source | 49,255,925Source | 32,248,852Source |
| Other IncomeUSD | — | — | 6,740Source | — | 2,271Source | 14,991Source | 8,145Source | 12,485Source | 45,421Source | 7,471Source | 67,657Source | 190,582Source |
| Research and Development ExpenseUSD | — | — | 20,359,098Source | 11,807,867Source | 28,866,292Source | 22,047,254Source | 27,376,912Source | 18,915,572Source | 84,454,595Source | 49,968,585Source | 36,448,039Source | 21,816,949Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 2,261,642Source | — | — | — | — | 0Source | 22,270,465Source | 25,178,066Source | 2,600,000Source |
Filing attachments
capr-20260824xex99d1.htm · 8-K · 2026-08-24
EX-99.1 2 capr-20260824xex99d1.htm EX-99.1 Exhibit 99.1 Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA - New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication - SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) - Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeut…
Read attachment ↗capr-20260813xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 capr-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Deramiocel Biologics License Application (BLA) under active FDA review HOPE-3 Phase 3 results published in The Lancet; primary endpoint of upper limb function achieved at p=0.029 Cash, cash equivalents and marketable securities of approximately $238 million as of June 30, 2026 Conference call and webcast today at 4:30 p.m. ET …
Read attachment ↗capr-20260729xex99d1.htm · 8-K · 2026-07-29
EX-99.1 2 capr-20260729xex99d1.htm EX-99.1 Exhibit 99.1 The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy --Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinicall…
Read attachment ↗capr-20260626xex99d1.htm · 8-K · 2026-06-26
EX-99.1 2 capr-20260626xex99d1.htm EX-99.1 Exhibit 99.1 Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - Advisory Committee meeting scheduled for July 29, 2026 - - Company's Biologics License Application on track with PDUFA target action date of August 22, 2026 - SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) - Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative ce…
Read attachment ↗capr-20260512xex99d1.htm · 8-K · 2026-05-12
EX-99.1 2 capr-20260512xex99d1.htm EX-99.1 Exhibit 99.1 Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb…
Read attachment ↗capr-20260507xex99d1.htm · 8-K · 2026-05-07
EX-99.1 2 capr-20260507xex99d1.htm EX-99.1 Exhibit 99.1 Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy -Complaint outlines its distribution partner’s failure to prepare for launch of DMD therapy; Capricor seeks to rescind the agreement while advancing plans to ensure treatment reaches patients- SAN DIEGO, May 7, 2026 -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and ex…
Read attachment ↗